<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation of renal osteodystrophy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation of renal osteodystrophy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Evaluation of renal osteodystrophy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas Nickolas, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">L Darryl Quarles, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Renal osteodystrophy collectively constitutes a group of abnormalities in bone morphology or histology that are an important component of mineral bone disorders among patients with chronic kidney disease (CKD-MBD). The bone abnormalities resulting from loss of kidney function render patients with CKD vulnerable to fractures.</p><p>This topic reviews the evaluation of renal osteodystrophy with noninvasive tests and with a bone biopsy, when indicated.</p><p>Other related topics are discussed in detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>An overview of CKD-MBD (see  <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of secondary hyperparathyroidism (see  <a class="medical medical_review" href="/z/d/html/1964.html" rel="external">"Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">"Management of secondary hyperparathyroidism in adult patients on dialysis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CKD and osteoporosis (see  <a class="medical medical_review" href="/z/d/html/13914.html" rel="external">"Osteoporosis in patients with chronic kidney disease: Diagnosis and evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/114322.html" rel="external">"Osteoporosis in patients with chronic kidney disease: Management"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone disease after kidney transplantation (see  <a class="medical medical_review" href="/z/d/html/100623.html" rel="external">"Kidney transplantation in adults: Bone disease after kidney transplantation"</a>)</p><p></p><p class="headingAnchor" id="H2440402248"><span class="h1">OVERVIEW OF NORMAL BONE</span><span class="headingEndMark"> — </span>Bone is a dynamic tissue that is constantly undergoing remodeling in response to changes in hormones and environmental factors. Osteocytes, embedded in bone, are the master regulators of bone and mineral homeostasis. Also present in the bone are osteoclasts, which resorb bone, and osteoblasts, which generate a mineralizable extracellular matrix (ie, osteoid) to replace resorbed bone. </p><p>The purpose of obtaining a bone biopsy is to determine the underlying bone pathology and its cause. Quantitative bone histomorphometry performed on bone biopsies provides an assessment of osteoblast-mediated bone formation and mineralization of extracellular matrix, the degree of osteoclast-mediated bone resorption, structure of trabecular and cortical bone, toxic metal accumulation, and the condition of the bone marrow space. With bone histomorphometry using the Goldner-Masson (trichrome) stain under light microscopy, normal bone osteoid appears red-brown and mineralized bone appears blue  (<a class="graphic graphic_picture graphicRef66330" href="/z/d/graphic/66330.html" rel="external">picture 1</a>). Under fluorescent light, the osteoid appears orange and the mineralized bone appears green. The luminescent <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> bands represent the formation of active mineralized bone beneath the osteoid surface.</p><p class="bulletIndent1">The osteoid is lamellar, present on a modest amount of the bone surface (&lt;25 percent), and covered with mature osteoblasts (approximately 40 percent). Bone resorption is minimal (&lt;7 percent), and osteoclasts are present on a small percentage of the bone surface (&lt;2 percent). </p><p></p><p class="headingAnchor" id="H216324550"><span class="h1">SUBTYPES OF RENAL OSTEODYSTROPHY</span><span class="headingEndMark"> — </span>Renal osteodystrophy refers to specific changes in bone histology associated with chronic kidney disease (CKD) [<a href="#rid1">1,2</a>]. It is an important component of chronic kidney disease-mineral and bone disorder (CKD-MBD). (See  <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)", section on 'Introduction and definitions'</a>.)</p><p>Traditionally, four main subtypes of renal osteodystrophy are recognized: osteitis fibrosa cystica, adynamic bone disease, osteomalacia, and mixed uremic osteodystrophy. These subtypes represent changes in bone turnover (or remodeling), mineralization, and volume, which comprise the more recent TMV classification (see <a class="local">'TMV classification'</a> below). The pathologic features of these four subtypes are presented below.</p><p class="headingAnchor" id="H804426880"><span class="h2">Osteitis fibrosa cystica</span><span class="headingEndMark"> — </span>Osteitis fibrosa cystica (OFC) is functionally characterized by high bone turnover (ie, high bone formation and resorption), typically caused by elevated circulating parathyroid hormone (PTH) levels.</p><p></p><p>There is a marked increase in the number and activity of osteoblasts and osteoclasts and an increase in woven osteoid and marrow fibrosis  (<a class="graphic graphic_picture graphicRef63957" href="/z/d/graphic/63957.html" rel="external">picture 2</a>). The woven osteoid represents disordered collagen that contrasts with the parallel collagen strands observed in normal bone. Distinct <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> labels cover the majority of bone surfaces, indicating accelerated bone formation and the absence of a mineralization defect. The decrease in mineralization is believed to be relative to the marked increase in bone turnover.</p><p class="headingAnchor" id="H2386595226"><span class="h2">Adynamic bone disease</span><span class="headingEndMark"> — </span>Adynamic bone disease (ABD) is characterized by low bone turnover (ie, low bone formation and resorption) due to reductions in both osteoblast and osteoclast activity [<a href="#rid3">3,4</a>]. Low bone turnover is usually due to excessive suppression of the parathyroid glands by medication (eg, <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a> or calcium-containing phosphate binders) or parathyroidectomy, but resistance to the bone stimulatory effects of PTH may contribute [<a href="#rid5">5,6</a>]. Low turnover is observed in a substantial subset of patients following successful kidney transplantation.</p><p>These defects are manifested histologically by thin osteoid seams that display no active mineralization, inactive-appearing osteoblasts, and fewer osteoclasts and bone resorptive surfaces  (<a class="graphic graphic_picture graphicRef75592" href="/z/d/graphic/75592.html" rel="external">picture 3</a>). (See  <a class="medical medical_review" href="/z/d/html/91082.html" rel="external">"Adynamic bone disease associated with chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H3126028568"><span class="h2">Osteomalacia</span><span class="headingEndMark"> — </span>Osteomalacia (OM) is characterized by reduced mineralization with increased unmineralized osteoid in conjunction with a prolonged mineralization lag time [<a href="#rid7">7,8</a>]. OM can be associated with either low or high bone turnover. Among patients with end-stage kidney disease (ESKD), low-turnover OM was previously attributed to aluminum deposition in bone. With the elimination of aluminium-based phosphate binders and introduction of stringent guidelines to minimize aluminum in dialysate water, OM has become uncommon in patients with ESKD [<a href="#rid9">9-12</a>]. However, other factors that impair mineralization, such as vitamin D deficiency and hypocalcemia (both typically associated with elevated PTH and high bone turnover), as well as hypophosphatemia, metabolic acidosis, and exposure to heavy metals, can also cause OM.</p><p>Histologically, OM is characterized by a marked increase in the volume of osteoid, an increase in the fraction of wide osteoid seams  (<a class="graphic graphic_picture graphicRef61773" href="/z/d/graphic/61773.html" rel="external">picture 4</a>), and delayed mineralization of bone protein. Examination under fluorescent light reveals little or no <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> deposition, suggesting low mineralization of bone. Aluminum can be detected histologically by staining a Villanueva-prestained section with aurintricarboxylic acid  (<a class="graphic graphic_picture graphicRef65065" href="/z/d/graphic/65065.html" rel="external">picture 5</a>). (See  <a class="medical medical_review" href="/z/d/html/1839.html" rel="external">"Aluminum toxicity in chronic kidney disease", section on 'Sources of aluminum'</a>.)</p><p class="headingAnchor" id="H2898233815"><span class="h2">Mixed uremic osteodystrophy</span><span class="headingEndMark"> — </span>Mixed uremic osteodystrophy (MUO) is a disorder with combined features of OFC and OM. The disease is characterized by high bone turnover and abnormal mineralization as seen with osteomalacia. As in OFC, the high bone turnover of MUO is mediated by increases in both osteoblast and osteoclast activity. A precise etiology and clinical correlate to MUO are not known. However, because MUO has features of both OFC and OM, elevated PTH, and/or factors contributing to impaired mineralization, such as vitamin D deficiency, hypocalcemia, hypophosphatemia, metabolic acidosis, and exposure to heavy metals could potentially result in MUO.</p><p></p><p class="bulletIndent1">MUO resembles OFC on light microscopy, except that there is a greater degree of osteoid accumulation, similar to that seen in OM  (<a class="graphic graphic_picture graphicRef52703" href="/z/d/graphic/52703.html" rel="external">picture 6</a>). Fluorescent microscopy shows impaired mineralization, as evidenced by diffuse <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> deposition and the absence of tetracycline in some bone-forming surfaces. There is also a prolonged mineralization lag time, which is the histologic hallmark of OM.</p><p></p><p class="headingAnchor" id="H3078776322"><span class="h2">TMV classification</span><span class="headingEndMark"> — </span>As an alternative to the traditional renal osteodystrophy subtype diagnostic classification, the turnover, mineralization, and volume (TMV) classification system was developed by the 2006 National Kidney Foundation working group on renal osteodystrophy to help clarify the interpretation of the bone biopsy and inform treatment decisions [<a href="#rid1">1</a>]. The TMV system employs three key histologic descriptors [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Turnover, which may be low, normal, or high</p><p class="bulletIndent1"><span class="glyph">●</span>Mineralization, which may be normal or abnormal</p><p class="bulletIndent1"><span class="glyph">●</span>Volume, which may be low, normal, or high</p><p></p><p>This classification is largely descriptive but provides less information than contained in the traditional histologic classifications described above. As an example, the TMV classification in OFC will differ for trabecular and cortical bone; where the TMV will be high turnover, accelerated mineralization, and high bone volume in trabecular bone, in cortical bone it will be high remodeling of the haversian system, increased endosteal mineralization rates, and lower cortical bone density due to increased cortical porosity. In the TMV classification for MUO, the mineralization rate as measured by <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> labeling would be impaired. The TMV system does not include quantification of the degree of peritrabecular fibrosis. OM in the TMV system would be coded as T, either high or low depending on the etiology, M would be impaired or decreased, and V would be variable depending on whether mineralized bone volume or total bone volume is being reported. For ABD, T is invariably low, M is low to absent (ie, very little presence of tetracycline labeling of bone surfaces), and V of trabecular bone is low, consistent with osteopenia. </p><p>In addition, the TMV system does not provide information about the cause of the bone disease or the risk of fracture. The report must be interpreted in the context of the patient, their medications, and their biochemical profile. As an example, a patient with OM might have abnormalities in serum phosphorus that need to be aggressively managed, may have vitamin D deficiency, or may need to be assessed for overexposure to heavy metals or iron. The term bone volume does not distinguish between trabecular bone loss from increased cortical porosity. </p><p class="headingAnchor" id="H1364559372"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Patients with renal osteodystrophy frequently are asymptomatic until they develop a fracture although some patients may develop bone pain, tendon rupture, muscle weakness, and, in growing children, growth retardation and skeletal deformities. There are no clinical features that clearly distinguish the various types of renal osteodystrophy, although patellar tendon rupture and leontiasis ossea point to secondary hyperparathyroidism. </p><p>Characteristic radiographic findings of osteitis fibrosa cystica include subperiosteal resorption and new bone formation, particularly at the radial aspect of the middle phalanges. Resorptive loss of bone may be also observed at the terminal phalanges, distal ends of the clavicles, and in the skull [<a href="#rid13">13</a>]. However, no skeletal imaging method can differentiate among renal osteodystrophy subtypes. Routine imaging with dual x-ray absorptiometry (DXA) to evaluate for renal osteodystrophy is not commonly performed but may be useful in identifying clinically important osteoporosis and fracture risk. (See  <a class="medical medical_review" href="/z/d/html/13914.html" rel="external">"Osteoporosis in patients with chronic kidney disease: Diagnosis and evaluation"</a>.)</p><p>Noninvasive bone turnover markers (such as intact parathyroid hormone [iPTH], bone-specific alkaline phosphatase [BSAP], intact procollagen type I N-terminal propeptide [PINP], and tartrate-resistant acid phosphatase isoform 5b [TRAP5b]), when used in combination, have improved accuracy in distinguishing high and low turnover bone disease in chronic kidney disease [<a href="#rid14">14</a>]. </p><p>The gold standard diagnostic method for identifying the type of renal osteodystrophy is <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> double-labeled iliac crest bone biopsy. (See <a class="local">'Initial noninvasive testing for all patients'</a> below and <a class="local">'Bone biopsy for selected patients'</a> below.)</p><p class="headingAnchor" id="H2782219600"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H3500298832"><span class="h2">When to suspect renal osteodystrophy</span><span class="headingEndMark"> — </span>Renal osteodystrophy should be suspected in all patients with advanced (ie, stages 3 to 5) chronic kidney disease (CKD). The prevalence of renal osteodystrophy increases as CKD stage and its associated metabolic derangements worsen [<a href="#rid15">15,16</a>]. Thus, by the time patients reach end-stage kidney disease (ESKD), most will have some form of metabolic bone disease [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H2263788569"><span class="h2">Initial noninvasive testing for all patients</span><span class="headingEndMark"> — </span>The evaluation and diagnosis of renal osteodystrophy are important for identifying and properly managing bone disease among patients with CKD, who have a significantly higher fracture risk compared with age- and sex-matched individuals without CKD [<a href="#rid17">17-25</a>]. In patients with CKD, it is also important to distinguish renal osteodystrophy from osteoporosis, as management of these conditions is different. (See  <a class="medical medical_review" href="/z/d/html/13914.html" rel="external">"Osteoporosis in patients with chronic kidney disease: Diagnosis and evaluation", section on 'Fracture risk in chronic kidney disease'</a>.)</p><p>A definitive diagnosis of renal osteodystrophy and the identification of histologic subtype are established by bone biopsy [<a href="#rid1">1,26</a>]. However, bone biopsies are rarely performed because there is insufficient expertise in their performance and interpretation at most academic centers [<a href="#rid27">27</a>].</p><p>For most patients, we and most other clinicians use serum intact parathyroid hormone (PTH) and bone-specific alkaline phosphatase (BSAP) levels as surrogate markers to distinguish among various types of renal osteodystrophy. However, these markers have limited sensitivity and specificity to correctly classify bone disease in an individual patient with CKD [<a href="#rid28">28,29</a>]. Some authors also use serum C-telopeptide of type I collagen (CTX) levels, which have also been shown to correlate well with bone turnover [<a href="#rid16">16</a>]. We do not routinely obtain bone imaging studies (eg, radiography, dual-energy x-ray absorptiometry [DXA]), as these tests do not reliably distinguish among the various types of renal bone lesions, although they may help identify the overall severity of the metabolic bone disorder. This approach is consistent with the 2017 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/2047.html" rel="external">"Bone physiology and biochemical markers of bone turnover"</a>.)</p><p>We use multiple values of PTH and bone turnover markers (BSAP and CTX) and trends over time rather than a single measurement since bone remodelling takes three or more months to achieve a steady state after changes in PTH. Serial measurements, however, have not been shown to improve accuracy. There is no uniform agreement about how frequently these biomarkers should be monitored. We generally monitor laboratory values with a schedule that is largely consistent with the KDIGO Clinical Practice Guidelines [<a href="#rid2">2</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intact PTH </strong>–<strong> </strong>As there is marked variability in different PTH assays, the same assay should be used for repeat measurements [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stage G3 – Measurements are based upon the baseline level and CKD progression </p><p class="bulletIndent2"><span class="glyph">•</span>Stage G4 – Measurements at least every 6 to 12 months</p><p class="bulletIndent2"><span class="glyph">•</span>Stage G5 – Measurements at least every 3 to 6 months</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BSAP </strong>– This is measured for patients with CKD stages G4 and G5 every 12 months, or more frequently when PTH is elevated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CTX </strong>– If used,<strong> </strong>this is measured for patients with CKD stages G4 and G5 once at baseline and then every 12 months.</p><p></p><p>If therapy is initiated to correct serum abnormalities or to treat renal osteodystrophy, the guidelines recommend that laboratory evaluation should be performed more frequently to ensure a response to therapy or to identify the need to adjust therapy [<a href="#rid2">2</a>]:</p><p>We use the following values for intact PTH, BSAP, and CTX to define the risk for specific subtypes of renal osteodystrophy. PTH, which measures parathyroid gland function and therefore the severity of secondary hyperparathyroidism, is an indirect marker of bone turnover that correlates with bone turnover markers. BSA, which is produced by osteoblasts, is a marker of osteoblastic activity. CTX is used as a marker of osteoclastic activity. The value of individual biochemical measurements in predicting bone histologic changes is relatively low, but values that are markedly elevated and/or that are progressively increasing with time are used in the diagnosis and treatment of bone disease in patients with CKD, as described below [<a href="#rid29">29-33</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Among patients on dialysis, a persistently low intact PTH (ie, &lt;100 pg/mL) suggests the diagnosis of adynamic bone disease (ABD) and a decreased risk of osteitis fibrosa cystica (OFC) and/or mixed uremic osteodystrophy (MUO).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients not on dialysis, an intact PTH that is persistently &lt;100 pg/mL may not reflect ABD, especially if serum calcium and phosphorus concentrations are within the normal range. Among such patients, ABD is suggested by a PTH concentration that was initially high and progressively decreases to less than the upper limit of normal for the PTH assay (generally 65 pg/mL) in the setting of treatment with active vitamin D analogs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients on or not on dialysis, intact PTH levels &gt;450 pg/mL suggest the diagnosis of OFC and/or MUO. Patients with intact PTH levels &gt;500 pg/mL are unlikely to have ABD [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients on or not on dialysis, intermediate intact PTH levels between 100 and 450 pg/mL are not useful to predict the type of renal osteodystrophy. Intermediate values may be associated with normal, high, or low turnover. In patients who have intermediate intact PTH concentrations and either symptoms of bone pain or unexplained hypercalcemia or hypophosphatemia, we assess the serum BSAP level. A high BSAP level (≥20 ng/mL) virtually excludes the diagnosis of ABD, particularly if the PTH is &gt;200 pg/mL [<a href="#rid35">35</a>], and suggests OFC or osteomalacia (OM); very high BSAP levels may suggest a diagnosis of OM [<a href="#rid15">15</a>]. By contrast, a low or borderline BSAP with a low serum PTH is consistent with, but does not establish, a diagnosis of ABD.</p><p></p><p class="headingAnchor" id="H2527510432"><span class="h2">Bone biopsy for selected patients</span><span class="headingEndMark"> — </span>A bone biopsy, performed after <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> labeling, is the gold standard for assessing the bone remodeling, mineralization, and structure. However, due to limited availability of expertise for the performance of bone biopsies and interpretation of histomorphometry, these are reserved for a selected group of patients. </p><p></p><p class="headingAnchor" id="H778218716"><span class="h3">Indications</span><span class="headingEndMark"> — </span>Controversy exists over the exact indications for bone biopsy. We agree with the KDIGO 2017 guidelines that a bone biopsy is indicated if knowledge of the type of renal osteodystrophy will affect treatment decisions [<a href="#rid28">28</a>]. </p><p>Clinical scenarios in which results from a bone biopsy may impact treatment decisions include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with unexplained bone pain or fractures (ie, with minimal or no trauma).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with unexplained, refractory hypercalcemia, to rule out the presence of multiple myeloma or granulomatous diseases, such as sarcoidosis, tuberculosis, or coccidiomycosis. This is generally a rare indication for a bone biopsy, and a bone marrow biopsy may be performed as an alternative. (See  <a class="medical medical_review" href="/z/d/html/839.html" rel="external">"Etiology of hypercalcemia"</a> and  <a class="medical medical_review" href="/z/d/html/836.html" rel="external">"Diagnostic approach to hypercalcemia"</a> and  <a class="medical medical_review" href="/z/d/html/841.html" rel="external">"Hypercalcemia in granulomatous diseases"</a> and  <a class="medical medical_review" href="/z/d/html/842.html" rel="external">"Hypercalcemia of malignancy: Mechanisms"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with suspicion of osteomalacia, based upon a history of aluminum exposure or other risk factors (eg, vitamin D deficiency, hypocalcemia, hypophosphatemia, metabolic acidosis). (See  <a class="medical medical_review" href="/z/d/html/1839.html" rel="external">"Aluminum toxicity in chronic kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have an atypical response to standard therapies for elevated PTH, to rule out atypical or unexpected bone pathology. As an example, in a patient who develops fractures after treatment, we would consider a bone biopsy to clarify whether ABD or OM is present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with ESKD who are planning to undergo parathyroidectomy because of bone-related symptoms (eg, bone pain and/or fractures) but who have an indeterminate PTH level (ie, &lt;800 pg/mL). The reason for the biopsy is to confirm the presence of PTH-mediated, high-turnover bone disease (provided that a confirmed diagnosis would alter treatment decisions). (See  <a class="medical medical_review" href="/z/d/html/1838.html" rel="external">"Refractory hyperparathyroidism and indications for parathyroidectomy in adult patients on dialysis", section on 'Symptomatic patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with bone pain and persistent serum intact PTH levels &lt;100 pg/mL despite withdrawal of <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a> or other vitamin D analogs, to confirm the diagnosis of adynamic bone disease. (See  <a class="medical medical_review" href="/z/d/html/91082.html" rel="external">"Adynamic bone disease associated with chronic kidney disease", section on 'Clinical features'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients in whom an inconsistency in biochemical parameters precludes a definitive interpretation (eg, levels of serum intact PTH are high, but BSAP levels are low).</p><p></p><p>We do not routinely perform a bone biopsy in patients who are going to receive bisphosphonate therapy, unless a diagnosis of low-turnover or adynamic bone disease cannot be excluded with noninvasive testing. The use of bisphosphonates in patients with CKD is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/114322.html" rel="external">"Osteoporosis in patients with chronic kidney disease: Management", section on 'Antiresorptive agents'</a>.)</p><p class="headingAnchor" id="H3545149258"><span class="h3">Procedure</span><span class="headingEndMark"> — </span>Bone biopsy is typically obtained from the iliac crest after the administration of two different time-spaced <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> markers [<a href="#rid36">36</a>]. The tetracycline markers bind to hydroxyapatite and emit fluorescence, which allows identification of bone. The rate of bone formation is determined by identifying the new bone formed in the time interval between the administration of different tetracycline labels.</p><p>A typical labeling schedule requires two three-day periods of <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> labeling, separated by 21 days. The second labeling period must be completed two days before the biopsy. As an example, we typically administer tetracycline 250 mg three times daily on days 23 to 25 before biopsy, followed by <a class="drug drug_general" data-topicid="9328" href="/z/d/drug information/9328.html" rel="external">demeclocycline</a> 300 mg three times daily on days 2 to 4 before biopsy.</p><p>Our preferred approach is to obtain a transcortical sample with an 8 mm trocar. However, emerging data suggest that a small 3.5 mm core obtained with a Jamshidi bone biopsy trephine likely provides equivalent information on dynamic and mineralization parameters [<a href="#rid37">37</a>]. The biopsy procedure can be performed under local anesthesia although moderate sedation is recommended to maximize patient comfort. Standard precautions for bleeding risk should be followed, and preoperative antibiotics are typically provided only to patients with a dialysis access or who are receiving immunosuppressive medications.</p><p>The bone specimen is stained with Goldner-Masson trichrome for differentiation of mineralized lamellar bone and nonmineralized osteoid and Villanueva stain for <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> fluorescence. At the discretion of the pathologist, in consultation with the referring clinician, the sample may also be stained for aluminum (using aurintricarboxylic acid), depending on indications or history or on other observed histologic features. As an example, staining for aluminum may be performed in a patient with a significant clinical history of aluminum exposure or if prominent findings of osteomalacia are observed by the pathologist. </p><p class="headingAnchor" id="H2931071789"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112930.html" rel="external">"Society guideline links: Chronic kidney disease-mineral and bone disorder"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Renal osteodystrophy collectively constitutes a group of abnormalities in bone morphology or histology that are an important component of mineral bone disorders among patients with chronic kidney disease (CKD-MBD). The bone abnormalities resulting from loss of kidney function render patients with CKD vulnerable to fractures. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subtypes of renal osteodystrophy </strong>– Traditionally, four main subtypes of renal osteodystrophy are recognized: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Osteitis fibrosa cystica – Osteitis fibrosa cystica (OFC) is functionally characterized by high bone turnover (ie, high bone formation and resorption), typically caused by elevated circulating parathyroid hormone (PTH) levels. (See <a class="local">'Osteitis fibrosa cystica'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adynamic bone disease – Adynamic bone disease (ABD) is characterized by low bone turnover (ie, low bone formation and resorption) due to reductions in both osteoblast and osteoclast activity  (<a class="graphic graphic_picture graphicRef75592" href="/z/d/graphic/75592.html" rel="external">picture 3</a>). (See <a class="local">'Adynamic bone disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Osteomalacia – Osteomalacia (OM) is characterized by reduced mineralization with increased unmineralized osteoid in conjunction with a prolonged mineralization lag time  (<a class="graphic graphic_picture graphicRef61773" href="/z/d/graphic/61773.html" rel="external">picture 4</a>). OM can be associated with either low or high bone turnover. (See <a class="local">'Osteomalacia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mixed uremic osteodystrophy – Mixed uremic osteodystrophy (MUO) is a disorder with combined features of OFC and OM. The disease is characterized by high bone turnover and abnormal mineralization as seen with osteomalacia. (See <a class="local">'Mixed uremic osteodystrophy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TMV classification </strong>– The turnover, mineralization, and volume (TMV) system classifies renal osteodystrophy based on bone turnover, mineralization, and volume as assessed by bone biopsy and histomorphometry. (See <a class="local">'TMV classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>– Patients with renal osteodystrophy frequently are asymptomatic until they develop a fracture although some patients may develop bone pain, tendon rupture, muscle weakness, and, in growing children, growth retardation and skeletal deformities. There are no clinical features that clearly distinguish the various types of renal osteodystrophy. Characteristic radiographic findings of osteitis fibrosa cystica include subperiosteal resorption and new bone formation, particularly at the radial aspect of the middle phalanges. Resorptive loss of bone may be also observed at the terminal phalanges, distal ends of the clavicles, and in the skull. However, no skeletal imaging method can differentiate among renal osteodystrophy subtypes. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation </strong>– Renal osteodystrophy should be suspected in all patients with advanced (ie, stages 3 to 5) CKD. A definitive diagnosis of renal osteodystrophy and the identification of histologic subtype are established by bone biopsy. However, bone biopsies are rarely performed because there is insufficient expertise in their performance and interpretation at most academic centers. For most patients, we and most other clinicians use serum intact parathyroid hormone (PTH) and bone-specific alkaline phosphatase (BSAP) levels as surrogate markers to distinguish among various types of renal osteodystrophy. However, these markers have limited sensitivity and specificity to correctly classify bone disease in an individual patient with CKD. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="headingAnchor" id="H3195485557"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael Berkoben, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945.</a></li><li><a class="nounderline abstract_t">Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int. 2017;92:26-36. Kidney Int 2017; 92:1558.</a></li><li><a class="nounderline abstract_t">Martin KJ, Olgaard K, Coburn JW, et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 2004; 43:558.</a></li><li><a class="nounderline abstract_t">Gal-Moscovici A, Popovtzer MM. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol 2005; 63:284.</a></li><li><a class="nounderline abstract_t">Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992; 75:145.</a></li><li><a class="nounderline abstract_t">Hernandez D, Concepcion MT, Lorenzo V, et al. Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant 1994; 9:517.</a></li><li><a class="nounderline abstract_t">Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995; 333:166.</a></li><li><a class="nounderline abstract_t">Fournier A, Morinière P, Ben Hamida F, et al. Use of alkaline calcium salts as phosphate binder in uremic patients. Kidney Int Suppl 1992; 38:S50.</a></li><li><a class="nounderline abstract_t">National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1.</a></li><li><a class="nounderline abstract_t">D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003; :S73.</a></li><li><a class="nounderline abstract_t">Changsirikulchai S, Domrongkitchaiporn S, Sirikulchayanonta V, et al. Renal osteodystrophy in Ramathibodi Hospital: histomorphometry and clinical correlation. J Med Assoc Thai 2000; 83:1223.</a></li><li><a class="nounderline abstract_t">Moe SM, Drüeke TB. A bridge to improving healthcare outcomes and quality of life. Am J Kidney Dis 2004; 43:552.</a></li><li><a class="nounderline abstract_t">Misiorowski W, Czajka-Oraniec I, Kochman M, et al. Osteitis fibrosa cystica-a forgotten radiological feature of primary hyperparathyroidism. Endocrine 2017; 58:380.</a></li><li><a class="nounderline abstract_t">Jørgensen HS, Behets G, Viaene L, et al. Diagnostic Accuracy of Noninvasive Bone Turnover Markers in Renal Osteodystrophy. Am J Kidney Dis 2022; 79:667.</a></li><li><a class="nounderline abstract_t">Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 2011; 26:1368.</a></li><li><a class="nounderline abstract_t">Salam S, Gallagher O, Gossiel F, et al. Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy. J Am Soc Nephrol 2018; 29:1557.</a></li><li><a class="nounderline abstract_t">Denburg MR, Kumar J, Jemielita T, et al. Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study. J Am Soc Nephrol 2016; 27:543.</a></li><li><a class="nounderline abstract_t">Nitsch D, Mylne A, Roderick PJ, et al. Chronic kidney disease and hip fracture-related mortality in older people in the UK. Nephrol Dial Transplant 2009; 24:1539.</a></li><li><a class="nounderline abstract_t">Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 2006; 17:3223.</a></li><li><a class="nounderline abstract_t">Ensrud KE, Lui LY, Taylor BC, et al. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 2007; 167:133.</a></li><li><a class="nounderline abstract_t">Dooley AC, Weiss NS, Kestenbaum B. Increased risk of hip fracture among men with CKD. Am J Kidney Dis 2008; 51:38.</a></li><li><a class="nounderline abstract_t">Maravic M, Ostertag A, Torres PU, Cohen-Solal M. Incidence and risk factors for hip fractures in dialysis patients. Osteoporos Int 2014; 25:159.</a></li><li><a class="nounderline abstract_t">Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58:396.</a></li><li><a class="nounderline abstract_t">Naylor KL, Jamal SA, Zou G, et al. Fracture Incidence in Adult Kidney Transplant Recipients. Transplantation 2016; 100:167.</a></li><li><a class="nounderline abstract_t">Ball AM, Gillen DL, Sherrard D, et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA 2002; 288:3014.</a></li><li><a class="nounderline abstract_t">Chapter 1: Introduction and definition of CKD-MBD and the development of the guideline statements. Kidney Int 2009; 76113:S3.</a></li><li><a class="nounderline abstract_t">Evenepoel P, D'Haese P, Bacchetta J, et al. Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative-a position paper. Nephrol Dial Transplant 2017; 32:1608.</a></li><li><a class="nounderline abstract_t">Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int 2017; 92:26.</a></li><li><a class="nounderline abstract_t">Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis 2016; 67:559.</a></li><li><a class="nounderline abstract_t">Moe SM. Management of renal osteodystrophy in peritoneal dialysis patients. Perit Dial Int 2004; 24:209.</a></li><li><a class="nounderline abstract_t">Cavalier E, Souberbielle JC, Delanaye P. PTH determination in hemodialyzed patients-A laboratory perspective. Semin Dial 2019; 32:490.</a></li><li><a class="nounderline abstract_t">Sturgeon CM, Sprague SM, Metcalfe W. Variation in parathyroid hormone immunoassay results--a critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant 2011; 26:3440.</a></li><li><a class="nounderline abstract_t">Hughes-Austin JM, Katz R, Semba RD, et al. Biomarkers of Bone Turnover Identify Subsets of Chronic Kidney Disease Patients at Higher Risk for Fracture. J Clin Endocrinol Metab 2020; 105:e2903.</a></li><li><a class="nounderline abstract_t">Barreto FC, Barreto DV, Moysés RM, et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008; 73:771.</a></li><li><a class="nounderline abstract_t">Ureña P, Hruby M, Ferreira A, et al. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996; 7:506.</a></li><li><a class="nounderline abstract_t">Hodgson SF. Skeletal remodeling and renal osteodystrophy. Semin Nephrol 1986; 6:42.</a></li><li><a class="nounderline abstract_t">Novel-Catin E, Pelletier S, Fouque D, et al. Quantitative histomorphometric analysis of halved iliac crest bone biopsies yield comparable ROD diagnosis as full 7.5mm wide samples. Bone 2020; 138:115460.</a></li></ol></div><div id="topicVersionRevision">Topic 7239 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16641930" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29153145" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int. 2017;92:26-36.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981615" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15847255" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1619003" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7522307" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7791820" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Renal osteodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1405382" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Use of alkaline calcium salts as phosphate binder in uremic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14520607" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12753271" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11143489" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Renal osteodystrophy in Ramathibodi Hospital: histomorphometry and clinical correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981614" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A bridge to improving healthcare outcomes and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28900835" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Osteitis fibrosa cystica-a forgotten radiological feature of primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34710517" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Diagnostic Accuracy of Noninvasive Bone Turnover Markers in Renal Osteodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21611975" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29555831" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26139439" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19075194" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Chronic kidney disease and hip fracture-related mortality in older people in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17005938" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Relationship between moderate to severe kidney disease and hip fracture in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17242313" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Renal function and risk of hip and vertebral fractures in older women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18155531" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Increased risk of hip fracture among men with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23835863" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Incidence and risk factors for hip fractures in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10886587" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Increased risk of hip fracture among patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26154389" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Fracture Incidence in Adult Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12479766" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Risk of hip fracture among dialysis and renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26746396" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Chapter 1: Introduction and definition of CKD-MBD and the development of the guideline statements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28339949" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative-a position paper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28646995" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26321176" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15185768" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Management of renal osteodystrophy in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31631422" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : PTH determination in hemodialyzed patients-A laboratory perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22039013" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Variation in parathyroid hormone immunoassay results--a critical governance issue in the management of chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32474604" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Biomarkers of Bone Turnover Identify Subsets of Chronic Kidney Disease Patients at Higher Risk for Fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18185506" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8704118" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2440086" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Skeletal remodeling and renal osteodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32485361" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Quantitative histomorphometric analysis of halved iliac crest bone biopsies yield comparable ROD diagnosis as full 7.5mm wide samples.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
